Navigation Links
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:7/9/2009

gain over time. To date, the only highly effective treatment option is surgical and limited to the minority of patients who have advanced to the most severe forms of obesity," said Steven R. Smith, M.D., professor and assistant director of clinical research at the Pennington Biomedical Research Center. "Providing the over 80 million overweight and obese Americans who have a BMI less than 35 kg/m2 with safe treatment options that offer compelling weight loss would be a significant advancement in obesity drug development."

The combination therapy was well tolerated, and no cardiovascular or neuropsychiatric (such as anxiety or depression) safety signals were observed. Consistent with previous clinical experience, the most common side effects seen with pramlintide/metreleptin combination treatment were injection site adverse events and nausea, which were mostly mild or moderate and transient in nature.

"These findings provide us with valuable data that will inform our clinical and product development strategy moving forward," said Christian Weyer, M.D., vice president, corporate development, diabetes and obesity at Amylin Pharmaceuticals. "Our integrated neurohormonal approach to obesity provides a broad research and development platform that has the potential to yield transformational therapies that address a range of unmet patient needs across the various classes of obesity."

Study Details

This Phase 2, 28-week, double-blind, placebo-controlled multi-center study randomized 608 obese or overweight patients with a BMI ranging from 27-45 kg/m2. Patients were well-distributed across this BMI range, with approximately 40% of patients at a starting BMI less than 35 kg/m2. Following a one-week placebo lead-in period, study subjects were randomized in a balanced fashion to receive twice-daily therapy with one of the following eight treatment regimens: 1) placebo/placebo; 2) pramlintide 360 mcg/placebo; 3)
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
2. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
3. Amylin Announces Preliminary Tabulation of Annual Meeting Results
4. Amylin Responds to Eastbourne Letter
5. Amylin Comments on RiskMetrics Report
6. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
7. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
8. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
9. Amylin Issues Statement in Response to Carl Icahn
10. Icahn Asks Amylin to Allow Discussions With Eastbourne
11. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)... 2, 2014 Culot brings life ... lab management services  BioData, producer of Labguru, ... to announce the appointment of Louis Culot ... as VP Marketing and Business Development at BioDiscovery Inc., ... clinical applications. Previously, Culot worked for 17 ...
(Date:8/31/2014)... , Aug. 31, 2014 Wockhardt Limited ... Discovery program in Anti-Infective research when two of its ... Qualified Infectious Disease Product (QIDP) status from U.S. Food ... drugs which act against pathogens which have a high ... identified by Centre for Disease Control (a top U.S. ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... Kauten is taking direct aim at three unfavorable metrics, and ... , ,Kauten, CEO of QBI Life Sciences , recently ... Polymeric Micelles, a core product. The screening, which employed UGT1A1, ... is used to determine whether a drug will become active ...
... that is developing technologies for the $6 billion worldwide wound ... , ,The company, which was honored during an awards ceremony ... of 27 finalists that presented business plans to a panel ... which drew 200 entries, it will collect prizes of at ...
... Telecommunications, Inc. has introduced the Enhanced Mail Guardian, ... for organizational networks. , ,Enhanced Mail Guardian's features include ... be customized to handle encrypted e-mails that are specific ... sort e-mails and attachments based on key words like ...
Cached Biology Technology:QBI's PreserveX product passes initial test 2QBI's PreserveX product passes initial test 3MatriLab wins Governor's Business Plan Contest 2MatriLab wins Governor's Business Plan Contest 3MatriLab wins Governor's Business Plan Contest 4
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
(Date:8/31/2014)... A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... stomach cramps, has been developed by a team at ... the research team has demonstrated that it is possible ... which would lead to rapid diagnosis of the ... could be possible to identify different strains of the ...
(Date:8/31/2014)... of satellite data from the last 19 years reveals that ... the coast of Antarctica to rise by 2cm more than ... of Southampton detected the rapid rise in sea-level by studying ... million square kilometres. , The melting of the ... has contributed an excess of around 350 gigatonnes of freshwater ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... research shows an increased risk of ischemic stroke in postmenopausal ... found in baked goods, fried foods, and packaged products. Study ... journal published by Wiley-Blackwell on behalf of the American Neurological ... the stroke risk caused by a diet high in trans ...
... NY, February 29, 2012Although industrial parks are often ... which they reside, they can also consume environmental ... affect human health and quality of life. A ... ( http://www.liebertpub.com/ees ), a peer-reviewed journal from ...
... supercomputer has completed the first phase of an ... powerful scientific computing systems in the world. ... this month. The testing suite included leading scientific ... fusion, and combustion. Jaguar, manufactured by Cray ...
Cached Biology News:Postmenopausal women at greater risk of stroke from high trans fat intake 2Can industrial parks be more environmentally friendly? 2ORNL completes first phase of Titan supercomputer transition 2
... 1, active MW: 34.2kDa Formulation: 10mM ... Brij-35, 1mM dithiothreitiol with 50% glycerol ... to the Certificate of Analysis for ... salt precipitation followed by gel filtration ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Thermal Printer Paper for Monolight(tm) Luminometer 1 each...
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Biology Products: